Generation of antigen-specific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation

Clinical Immunology

Volumn 160, Issue 1, 2015, Pages 103-123

  Engman, Carl ^a   Wen, Yi ^b,c   Meng, Wilson S ^b   Bottino, Rita ^a   Trucco, Massimo ^a   Giannoukakis, Nick ^a  

^a ALLEGHENY HEALTH NETWORK   (United States)

^b Mylan School of Pharmacy   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antigen; Dendritic; Diabetes; Immunotherapy; Microspheres; Tolerogenic

Indexed keywords

ANTIGEN; MICROSPHERE; TRANSCRIPTION FACTOR FOXP3; VACCINE; ANTISENSE OLIGONUCLEOTIDE; B7 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; GLYCOPROTEIN P 15095; LYMPHOCYTE ANTIGEN RECEPTOR; PTPRC PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; IN VIVO STUDY; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TARGET ORGAN; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; CELL CULTURE; CELL MOTION; CYTOLOGY; DENDRITIC CELL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GENE SILENCING; GENETICS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREAS; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD40; ANTIGENS, CD45; ANTIGENS, CD80; ANTIGENS, CD86; BLOOD GLUCOSE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCKDOWN TECHNIQUES; HYPERGLYCEMIA; LYMPH NODES; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED NOD; MICE, TRANSGENIC; MICROSPHERES; OLIGONUCLEOTIDES, ANTISENSE; PANCREAS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, REGULATORY; VACCINES;

EID: 84940448968     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.004     Document Type: Article

References (118)

1. Atkinson M.A., Eisenbarth G.S., Michels A.W. Type 1 diabetes. Lancet 2014, 383:69-82.
2. Jayasimhan A., Mansour K.P., Slattery R.M. Advances in our understanding of the pathophysiology of Type 1 diabetes: lessons from the NOD mouse. Clin. Sci. (Lond.) 2014, 126:1-18.
3. Roep B.O. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann. N. Y. Acad. Sci. 2007, 1103:1-10.
4. Gorus F.K., Keymeulen B., Veld P.A., Pipeleers D.G. Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase. Expert. Rev. Clin. Immunol. 2013, 9:1173-1183.
5. Achenbach P., Bonifacio E., Ziegler A.G. Predicting type 1 diabetes. Curr. Diab. Rep. 2005, 5:98-103.
6. von Herrath M., Peakman M., Roep B. Progress in immune-based therapies for type 1 diabetes. Clin. Exp. Immunol. 2013, 172:186-202.
7. Staeva T.P., Chatenoud L., Insel R., Atkinson M.A. Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 2013, 62:9-17.
8. Thomas H.R., Gitelman S.E. Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr. Diabetes 2013, 14:311-321.
9. Bach J.F., Chatenoud L. A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. Semin. Immunol. 2011, 23:174-181.
10. Ben Nasr M., D'Addio F., Usuelli V., Tezza S., Abdi R., Fiorina P. The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol. Res. 2014, pii: S1043-6618(14)00118-2.
11. Michels A.W., von Herrath M. 2011 Update: antigen-specific therapy in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18:235-240.
12. Ryden A.K., Wesley J.D., Coppieters K.T., Von Herrath M.G. Non-antigenic and antigenic interventions in type 1 diabetes. Hum. Vaccin. Immunother. 2014, 10:838-846.
13. Schloot N.C., Cohen I.R. DiaPep277(R) and immune intervention for treatment of type 1 diabetes. Clin. Immunol. 2013, 149:307-316.
14. Phillips B., Trucco M., Giannoukakis N. Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?. Clin. Dev. Immunol. 2011, 2011:432016.
15. Friedman R.S., Lindsay R.S., Lilly J.K., Nguyen V., Sorensen C.M., Jacobelli J., Krummel M.F. An evolving autoimmune microenvironment regulates the quality of effector T cell restimulation and function. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:9223-9228.
16. Ferris S.T., Carrero J.A., Mohan J.F., Calderon B., Murphy K.M., Unanue E.R. A minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes. Immunity 2014, 41:657-669.
17. Calderon B., Carrero J.A., Unanue E.R. The central role of antigen presentation in islets of Langerhans in autoimmune diabetes. Curr. Opin. Immunol. 2014, 26:32-40.
18. Coppieters K., Martinic M.M., Kiosses W.B., Amirian N., von Herrath M. A novel technique for the in vivo imaging of autoimmune diabetes development in the pancreas by two-photon microscopy. PLoS One 2010, 5:e15732.
19. Melli K., Friedman R.S., Martin A.E., Finger E.B., Miao G., Szot G.L., Krummel M.F., Tang Q. Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues. J. Immunol. 2009, 182:2590-2600.
20. Calderon B., Suri A., Miller M.J., Unanue E.R. Dendritic cells in islets of Langerhans constitutively present beta cell-derived peptides bound to their class II MHC molecules. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:6121-6126.
21. Haase C., Skak K., Michelsen B.K., Markholst H. Local activation of dendritic cells leads to insulitis and development of insulin-dependent diabetes in transgenic mice expressing CD154 on the pancreatic beta-cells. Diabetes 2004, 53:2588-2595.
22. Aspord C., Rome S., Thivolet C. Early events in islets and pancreatic lymph nodes in autoimmune diabetes. J. Autoimmun. 2004, 23:27-35.
23. Waithman J., Allan R.S., Kosaka H., Azukizawa H., Shortman K., Lutz M.B., Heath W.R., Carbone F.R., Belz G.T. Skin-derived dendritic cells can mediate deletional tolerance of class I-restricted self-reactive T cells. J. Immunol. 2007, 179:4535-4541.
24. Santabarbara S., Kuprov I., Hore P.J., Casal A., Heathcote P., Evans M.C. Analysis of the spin-polarized electron spin echo of the [P700+ A1-] radical pair of photosystem I indicates that both reaction center subunits are competent in electron transfer in cyanobacteria, green algae, and higher plants. Biochemistry 2006, 45:7389-7403.
25. Allan R.S., Waithman J., Bedoui S., Jones C.M., Villadangos J.A., Zhan Y., Lew A.M., Shortman K., Heath W.R., Carbone F.R. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006, 25:153-162.
26. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., Davey G.M., Wilson N.S., Carbone F.R., Villadangos J.A. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 2004, 199:9-26.
27. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
28. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 2002, 23:445-449.
29. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
30. Steinman R.M., Turley S., Mellman I., Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 2000, 191:411-416.
31. Vlad G., Cortesini R., Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J. Immunol. 2005, 174:5907-5914.
32. Clare-Salzler M., Mullen Y. Marked dendritic cell-T cell cluster formation in the pancreatic lymph node of the non-obese diabetic mouse. Immunology 1992, 76:478-484.
33. Hoglund P., Mintern J., Waltzinger C., Heath W., Benoist C., Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J. Exp. Med. 1999, 189:331-339.
34. Shimizu J., Carrasco-Marin E., Kanagawa O., Unanue E.R. Relationship between beta cell injury and antigen presentation in NOD mice. J. Immunol. 1995, 155:4095-4099.
35. Ehl S., Hombach J., Aichele P., Rulicke T., Odermatt B., Hengartner H., Zinkernagel R., Pircher H. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J. Exp. Med. 1998, 187:763-774.
36. Ludewig B., Ehl S., Karrer U., Odermatt B., Hengartner H., Zinkernagel R.M. Dendritic cells efficiently induce protective antiviral immunity. J. Virol. 1998, 72:3812-3818.
37. Ludewig B., Odermatt B., Landmann S., Hengartner H., Zinkernagel R.M. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J. Exp. Med. 1998, 188:1493-1501.
38. Christen U., von Herrath M.G. Transgenic animal models for type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse model. Transgenic Res. 2002, 11:587-595.
39. Christen U., von Herrath M.G. Manipulating the type 1 vs type 2 balance in type 1 diabetes. Immunol. Res. 2004, 30:309-325.
40. Christen U., von Herrath M.G. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol. Immunol. 2004, 40:1113-1120.
41. von Herrath M.G. Regulation of virally induced autoimmunity and immunopathology: contribution of LCMV transgenic models to understanding autoimmune insulin-dependent diabetes mellitus. Curr. Top. Microbiol. Immunol. 2002, 263:145-175.
42. Chappert P., Leboeuf M., Rameau P., Stockholm D., Liblau R., Danos O., Davoust J.M., Gross D.A. Antigen-driven interactions with dendritic cells and expansion of Foxp3+ regulatory T cells occur in the absence of inflammatory signals. J. Immunol. 2008, 180:327-334.
43. DiPaolo R.J., Brinster C., Davidson T.S., Andersson J., Glass D., Shevach E.M. Autoantigen-specific TGFbeta-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J. Immunol. 2007, 179:4685-4693.
44. Lehner T. Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation. Immunology 2008, 123:40-44.
45. Onishi Y., Fehervari Z., Yamaguchi T., Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10113-10118.
46. Xia C.Q., Qiu Y., Peng R., Lo-Dauer J., Clare-Salzler M.J. Apoptotic non-beta cells suppress beta cell antigen-reactive T cells and induce beta cell antigen-specific regulatory T cells. Ann. N. Y. Acad. Sci. 2008, 1150:167-170.
47. Van Brussel I., Lee W.P., Rombouts M., Nuyts A.H., Heylen M., De Winter B.Y., Cools N., Schrijvers D.M. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?. Autoimmun. Rev. 2014, 13:138-150.
48. Thomas R. Dendritic cells as targets or therapeutics in rheumatic autoimmune disease. Curr. Opin. Rheumatol. 2014, 26:211-218.
49. Creusot R.J., Giannoukakis N., Trucco M., Clare-Salzler M.J., Fathman C.G. It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes 2014, 63:20-30.
50. Vassalli G. Dendritic Cell-Based Approaches for Therapeutic Immune Regulation in Solid-Organ Transplantation. J. Transplant. 2013, 2013:761429.
51. Raich-Regue D., Glancy M., Thomson A.W. Regulatory dendritic cell therapy: From rodents to clinical application. Immunol. Lett. 2014, 1(2):216-221.
52. Moreau A., Varey E., Bouchet-Delbos L., Cuturi M.C. Cell therapy using tolerogenic dendritic cells in transplantation. Transplant. Res. 2012, 1:13.
53. Giannoukakis N., Trucco M. Dendritic cell therapy for Type 1 diabetes suppression. Immunotherapy 2012, 4:1063-1074.
54. Di Caro V., Phillips B., Engman C., Harnaha J., Trucco M., Giannoukakis N. Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice. PLoS One 2014, 9:e83575.
55. Di Caro V., Phillips B., Engman C., Harnaha J., Trucco M., Giannoukakis N. Retinoic acid-producing, ex-vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B lymphocytes. Clin. Exp. Immunol. 2013, 174:302-317.
56. Harnaha J., Machen J., Wright M., Lakomy R., Styche A., Trucco M., Makaroun S., Giannoukakis N. Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes 2006, 55:158-170.
57. Machen J., Harnaha J., Lakomy R., Styche A., Trucco M., Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. 2004, 173:4331-4341.
58. Giannoukakis N., Phillips B., Finegold D., Harnaha J., Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011, 34:2026-2032.
59. Keselowsky B.G., Xia C.Q., Clare-Salzler M. Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes. Hum. Vaccin. 2011, 7:37-44.
60. Singh A., Suri S., Roy K. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 2009, 30:5187-5200.
61. Zhao X., Jain S., Benjamin Larman H., Gonzalez S., Irvine D.J. Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials 2005, 26:5048-5063.
62. Phillips B., Nylander K., Harnaha J., Machen J., Lakomy R., Styche A., Gillis K., Brown L., Lafreniere D., Gallo M., Knox J., Hogeland K., Trucco M., Giannoukakis N. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 2008, 57:1544-1555.
63. Chamarthy S.P., Kovacs J.R., McClelland E., Gattens D., Meng W.S. A cationic peptide consists of ornithine and histidine repeats augments gene transfer in dendritic cells. Mol. Immunol. 2003, 40:483-490.
64. Kovacs J.R., Tidball J., Ross A., Jia L., Zheng Y., Gawalt E.S., Meng W.S. Characterization of nickel-decorated PLGA particles anchored with a his-tagged polycation. J. Biomater. Sci. 2009, 20:1307-1320.
65. Zheng Y., Kovacs J.R., Gawalt E.S., Shen H., Meng W.S. Characterization of particles fabricated with poly(D, L-lactic-co-glycolic acid) and an ornithine-histidine peptide as carriers of oligodeoxynucleotide for delivery into primary dendritic cells. J Biomater Sci Polym Ed. 2006, 17(2):1389-1403.
66. Ma L., Qian S., Liang X., Wang L., Woodward J.E., Giannoukakis N., Robbins P.D., Bertera S., Trucco M., Fung J.J., Lu L. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes 2003, 52:1976-1985.
67. Lu L., Hsieh M., Oriss T.B., Morel P.A., Starzl T.E., Rao A.S., Thomson A.W. Generation of DC from mouse spleen cell cultures in response to GM-CSF: immunophenotypic and functional analyses. Immunology 1995, 84:127-134.
68. Fu F., Li Y., Qian S., Lu L., Chambers F., Starzl T.E., Fung J.J., Thomson A.W. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996, 62:659-665.
69. Barratt-Boyes S.M., Zimmer M.I., Harshyne L.A., Meyer E.M., Watkins S.C., Capuano S., Murphey-Corb M., Falo L.D., Donnenberg A.D. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J. Immunol. 2000, 164:2487-2495.
70. Thomas S.N., Vokali E., Lund A.W., Hubbell J.A., Swartz M.A. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 2014, 35:814-824.
71. Gamvrellis A., Walsh K., Tatarczuch L., Smooker P., Plebanski M., Scheerlinck J.P. Phenotypic analysis of ovine antigen presenting cells loaded with nanoparticles migrating from the site of vaccination. Methods 2013, 60:257-263.
72. Lukacs-Kornek V., Turley S.J. Self-antigen presentation by dendritic cells and lymphoid stroma and its implications for autoimmunity. Curr. Opin. Immunol. 2011, 23:138-145.
73. Crozat K., Tamoutounour S., Manh T.P.Vu., Fossum E., Luche H., Ardouin L., Guilliams M., Azukizawa H., Bogen B., Malissen B., Henri S., Dalod M. Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8alpha+type. J. Immunol. 2011, 187:4411-4415.
74. Azukizawa H., Dohler A., Kanazawa N., Nayak A., Lipp M., Malissen B., Autenrieth I., Katayama I., Riemann M., Weih F., Berberich-Siebelt F., Lutz M.B. Steady state migratory RelB+ langerin+dermal dendritic cells mediate peripheral induction of antigen-specific CD4+ CD25+ Foxp3+ regulatory T cells. Eur. J. Immunol. 2011, 41:1420-1434.
75. Luckashenak N., Schroeder S., Endt K., Schmidt D., Mahnke K., Bachmann M.F., Marconi P., Deeg C.A., Brocker T. Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 2008, 28:521-532.
76. Yoshino M., Yamazaki H., Shultz L.D., Hayashi S. Constant rate of steady-state self-antigen trafficking from skin to regional lymph nodes. Int. Immunol. 2006, 18:1541-1548.
77. Mullins D.W., Engelhard V.H. Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J. Immunol. 2006, 176:4535-4542.
78. Sixt M., Kanazawa N., Selg M., Samson T., Roos G., Reinhardt D.P., Pabst R., Lutz M.B., Sorokin L. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 2005, 22:19-29.
79. Sen D., Deerinck T.J., Ellisman M.H., Parker I., Cahalan M.D. Quantum dots for tracking dendritic cells and priming an immune response in vitro and in vivo. PLoS One 2008, 3:e3290.
80. Hamdy S., Elamanchili P., Alshamsan A., Molavi O., Satou T., Samuel J. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co-glycolic acid) nanoparticles. J. Biomed. Mater. Res. 2007, 81:652-662.
81. Kearney E.R., Pape K.A., Loh D.Y., Jenkins M.K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994, 1:327-339.
82. Bailey-Bucktrout S.L., Bluestone J.A. Regulatory T cells: stability revisited. Trends Immunol. 2011, 32:301-306.
83. Wan Y.Y., Flavell R.A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007, 445:766-770.
84. Giannoukakis N., Trucco M. Dendritic cell therapy for Type 1 diabetes suppression. Immunotherapy. 2012, 4(10):1063-1074.
85. Giannoukakis N. Tolerogenic dendritic cells for Type 1 diabetes. Immunotherapy 2013, 5:569-571.
86. Giannoukakis N. Immunoregulatory dendritic cells to treat autoimmunity are ready for the clinic. Interview by Katie Lockwood. Immunotherapy 2013, 5:919-921.
87. Phillips B., Trucco M., Giannoukakis N. Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?. Clin Dev Immunol. 2011, V2011. Article ID 432016.
88. Phillips B., Trucco M., Giannoukakis N. Drug delivery technologies for autoimmune disease. Expert Opin Drug Deliv. 2010, 7(11):1279-1289.
89. Rahimian S., Kleinovink J.W., Fransen M.F., Mezzanotte L., Gold H., Wisse P., Overkleeft H., Amidi M., Jiskoot W., Lowik C.W., Ossendorp F., Hennink W.E. Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8(+) T cell immune response. Biomaterials 2015, 37:469-477.
90. Chandrasekaran S., King M.R. Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy. Int J Mol Sci. 2014, 15(11):20209-20239.
91. Huck S.P., Tang S.C., Andrew K.A., Yang J., Harper J.L., Ronchese F. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors. Cancer Immunol. Immunother. 2008, 57:63-71.
92. Lesterhuis W.J., de Vries I.J., Schreibelt G., Lambeck A.J., Aarntzen E.H., Jacobs J.F., Scharenborg N.M., van de Rakt M.W., de Boer A.J., Croockewit S., van Rossum M.M., Mus R., Oyen W.J., Boerman O.C., Lucas S., Adema G.J., Punt C.J., Figdor C.G. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin. Cancer Res. 2011, 17:5725-5735.
93. Yamazaki S., Patel M., Harper A., Bonito A., Fukuyama H., Pack M., Tarbell K.V., Talmor M., Ravetch J.V., Inaba K., Steinman R.M. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2758-2763.
94. Yamazaki S., Inaba K., Tarbell K.V., Steinman R.M. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol. Rev. 2006, 212:314-329.
95. Waithman J., Zanker D., Xiao K, Oveissi S., Wylie B, Ng R., Tögel L., Chen W. Resident CD8(+) and migratory CD103(+) dendritic cells control. CD8 T cell immunity during acute influenza infection 2013, 8(6):e66136.
96. Carbone F.R., Belz G.T., Heath W.R. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol. 2004, 25:655-658.
97. Scheinecker C., McHugh R., Shevach E.M., Germain R.N. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J. Exp. Med. 2002, 196:1079-1090.
98. Calderon B., Unanue E.R. Antigen presentation events in autoimmune diabetes. Curr. Opin. Immunol. 2012, 24:119-128.
99. Gagnerault M.C., Luan J.J., Lotton C., Lepault F. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J. Exp. Med. 2002, 196:369-377.
100. Graham K.L., Krishnamurthy B., Fynch S., Mollah Z.U., Slattery R., Santamaria P., Kay T.W., Thomas H.E. Autoreactive cytotoxic T lymphocytes acquire higher expression of cytotoxic effector markers in the islets of NOD mice after priming in pancreatic lymph nodes. Am. J. Pathol. 2011, 178:2716-2725.
101. Marrero I., Vong A., Dai Y., Davies J.D. T cell populations in the pancreatic lymph node naturally and consistently expand and contract in NOD mice as disease progresses. Molecular Immunology. 2012, 52(1):9-18.
102. Marrero I., Vong A., Dai Y., Davies J.D. T cell populations in the pancreatic lymph node naturally and consistently expand and contract in NOD mice as disease progresses. Mol. Immunol. 2012, 52:9-18.
103. Turley S.J., Lee J.W., Dutton-Swain N., Mathis D., Benoist C. Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17729-17733.
104. Tsai S., Shameli A., Yamanouchi J., Clemente-Casares X., Wang J., Serra P., Yang Y., Medarova Z., Moore A., Santamaria P. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 2010, 32:568-580.
105. Huang L., Li L., Lemos H., Chandler P.R., Pacholczyk G., Baban B., Barber G.N., Hayakawa Y., McGaha T.L., Ravishankar B., Munn D.H., Mellor A.L. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J. Immunol. 2013, 191:3509-3513.
106. Peter M., Bode K., Lipford G.B., Eberle F., Heeg K., Dalpke A.H. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology 2008, 123:118-128.
107. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y.J., Blazar B.R., Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol. 2004, 173:4433-4442.
108. Klinman D.M., Zeuner R., Yamada H., Gursel M., Currie D., Gursel I. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann. N. Y. Acad. Sci. 2003, 1002:112-123.
109. Di Caro V., D'Anneo A., Phillips B., Engman C., Harnaha J., Trucco M., Giannoukakis N. Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity. Immunol. Res. 2011, 50:130-152.
110. Di Caro V., Phillips B., Engman C., Harnaha J., Trucco M., Giannoukakis N. Retinoic acid-producing, ex-vivo-generated human tolerogenic dendritic cells induce the proliferation of suppressive regulatory B-lymphocytes. Clin. Exp. Immunol. 2013, 174(2):302-317.
111. Hall J.A., Grainger J.R., Spencer S.P., Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunity 2011, 35:13-22.
112. Collins C.B., Aherne C.M., Kominsky D., McNamee E.N., Lebsack M.D., Eltzschig H., Jedlicka P., Rivera-Nieves J. Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. Gastroenterology 2011, 141:1821-1831.
113. Wang G., Zhong A., Wang S., Dong N., Sun Z., Xia J. Retinoic acid attenuates acute heart rejection by increasing regulatory T cell and repressing differentiation of Th17 cell in the presence of TGF-beta. Transpl. Int. 2010, 23:986-997.
114. Xiao S., Jin H., Korn T., Liu S.M., Oukka M., Lim B., Kuchroo V.K. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J. Immunol. 2008, 181:2277-2284.
115. Jaensson E., Uronen-Hansson H., Pabst O., Eksteen B., Tian J., Coombes J.L., Berg P.L., Davidsson T., Powrie F., Johansson-Lindbom B., Agace W.W. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J. Exp. Med. 2008, 205:2139-2149.
116. Hill J.A., Hall J.A., Sun C.M., Cai Q., Ghyselinck N., Chambon P., Belkaid Y., Mathis D., Benoist C. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells. Immunity 2008, 29:758-770.
117. Mucida D., Park Y., Kim G., Turovskaya O., Scott I., Kronenberg M., Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317:256-260.
118. Benson M.J., Pino-Lagos K., Rosemblatt M., Noelle R.J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J. Exp. Med. 2007, 204:1765-1774.